Radionuclide dosimetry and radioimmunotherapy of cancer

Radioimmunotherapy of Cancer

Volumn , Issue , 2000, Pages 21-55

  Meredith, Ruby F ^a   Buchsbaum, Donald J ^a   Knox, Susan J ^b  

^a The University of Alabama at Birmingham   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0009036711     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (146)

1. Goldenberg DM. Future role of radiolabeled monoclonal antibodies in oncological diagnosis and therapy. Semin Nucl Med 1989; 19:332-339.
2. Goldenberg DM. New developments in monoclonal antibodies for cancer detection and therapy. Cancer J Clin 1994; 44:43-64.
3. Meredith RF, Buchsbaum DJ. Radioimmunotherapy of solid tumors. In: Henkin RE, Boles MA, Dillehay GL, Halama JR, Karesh SM, Wagner RH, Zimmer AM, eds. Nuclear Medicine. St. Louis, MO: Mosby-Year Book, 1996:601-608.
4. Larson SM, Divgi CR, Scott A, Sgouros G, Graham MC, Kostakoglu L, Scheinberg D, Cheung NKV, Schlom J, Finn RD. Current status of radioimmunotherapy. Nucl Med Biol 1994; 21:785-792.
5. Sands H, Jones PL. Physiology of monoclonal antibody accretion by tumors. In: Goldenberg DM, ed. Cancer Imaging with Radiolabeled Antibodies. Boston: Kluwer Publishers, 1990:97-122.
6. Schlom J, Horan Hand P, Greiner JW, Colcher D, Shrivastav S, Carrasquillo JA, Reynolds JC, Larson SM, Raubitschek A. Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting. Cancer Res 1990; 50(suppl): 820s-827s.
7. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988; 48:7022-7032.
8. Baxter LT, Yuan F, Jain RK. Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: comparison with experimental data. Cancer Res 1992; 52:5838-5844.
9. Neuwelt EA, Barnett PA, Hellstrom KE, Hellstrom I, McCormick CI, Ramsey FL. Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. J Nucl Med 1994; 35:1831-1841.
10. van Osdol W, Fujimori K, Weinstein JN. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a “binding site barrier.'' Cancer Res 1991; 51:4776-4784.
11. Press OW, Eary JF, Appelbaum FR, Bernstein ID. Radiolabeled antibody therapy of lymphomas. In: DeVita VT, Hellman S Rosenberg SA, eds. Biologic Therapy of Cancer. Philadelphia: Lippincott Healthcare Publications, 1994:1-13.
12. Press OW, Eary JF, Appelbaum FR, Bernstein ID. Treatment of relapsed B cell lymphomas with high-dose radioimmunotherapy and bone marrow transplantation. In: Goldenberg DM, ed. Cancer Therapy with Radiolabeled Antibodies. Boca Raton, FL: CRC Press, 1995:229-237.
13. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, Matthews DC, Fisher LD, Bernstein ID. Radiola beled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329:1219-1224.
14. Bunn PA Jr, Carrasquillo JA, Keenan AM, Schroff RW, Foon KA, Hsu SM, Gazdar AF, Reynolds JC, Perentesis P, Larson SM. Imaging of T-cell lymphoma by radiolabelled monoclonal antibody. Lancet 1984; 2:1219-1221.
15. Shen S, DeNardo GL, O’Donnell RT, Yuan A, DeNardo DA, DeNardo SJ. Impact of splenomegaly on I-131-Lym-1 dosimetry and response for radioimmunotherapy in patients with B-lymphocytic malignancies. Tumor Targeting 1996; 2:175.
16. Kaminski MS, Zasadny KR, Frances IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, Glenn SD, Wahl RL. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329:459-465.
17. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, Grillo-Lopéz A, Chinn P, Varns C, Ning SC, Fowler S, Deb N, Becker M, Marquez C, Levy R. 90Y-labeled anti-CD20 monoclonal antibody therapy of recurrent B cell lymphoma. Clin Cancer Res 1996; 2:457-470.
18. Buchsbaum DJ. Experimental radioimmunotherapy and methods to increase therapeutic efficacy. In: Goldenberg DM, ed. Cancer Therapy with Radiolabeled Antibodies. Boca Raton, FL: CRC Press, 1995:115-140.
19. Knox SJ. Overview of studies on experimental radioimmunotherapy. Cancer Res 1995; 55(suppl):5832s-5836s.
20. Paganelli G, Magnani P, Siccardi AG, Fazio F. Clinical application of the avidinbiotin system for tumor targeting. In: Goldenberg D, ed. Cancer Therapy with Radiolabeled Antibodies. Boca Raton, FL: CRC Press, 1995:239-254.
21. Kuhn JA, Beatty BG, Wong JYC, Esteban JM, Wanek PM, Wall F, Buras RR, Williams LE, Beatty JD. Interferon enhancement of radioimmunotherapy for colon carcinoma. Cancer Res 1991; 51:2335-2339.
22. Greiner JW, Ullmann CD, Nieroda C, Qi C-F, Eggensperger D, Shimada S, Steinberg SM, Schlom J. Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with α-interferon. Cancer Res 1993; 53:600-608.
23. Roselli M, Guadagni F, Buonomo O, Belardi A, Vittorini V, Mariani-Costantini R, Greiner JW, Casciani CU, Schlom J. Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinomaassociated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen. J Clin Oncol 1996; 14:2031-2042.
24. Murray JL, Macey DJ, Grant EJ, Rosenblum MG, Kasi LP, Zhang HZ, Katz RL, Riger PT, LeBherz D, Bhadkamkar V, Greiner JW, Schlom J, Podoloff DA. Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following a-interferon treatment. Cancer Res 1995; 55(suppl):5925s-5928s.
25. Meredith R, Alvarez R, Partridge E, Khazaeli MB, Grizzle W. Enhanced intraperitoneal radioimmunotherapy with adjuvant interferon and Taxol. Int J Radiat Oncol Biol Phys 1997; 39(suppl 2):303.
26. Blumenthal RD, Sharkey RM, Goldenberg DM. Dose escalation of radioantibody in a mouse model with the use of recombinant human interleukin-1 and granulocyte macrophage colony-stimulating factor intervention to reduce myelosuppression. J Natl Cancer Inst 1992; 84:399-407.
27. Wheeler RH, Meredith RF, Saleh MN, Khazaeli MB, Murray JL, LoBuglio AF. A phase II trial of IL-1 radioimmunotherapy (RIT) in patients (Pts) with metastatic colon cancer. Proc ASCO 1994; 13:295.
28. Leichner PK, Akabani G, Colcher D, Harrison KA, Hawkins WG, Eckblade M, Baranowska-Kortylewica J, Augustine SC, Wisecarver J, Tempero MA. Patientspecific dosimetry of indium-111 and yttrium-90-labeled monoclonal antibody CC49. J Nucl Med 1997; 38:512-516.
29. Vriesendorp HM, Shao Y, Blum JE, Quadri SM, Williams JR. Fractionated intravenous administration of 90Y-labeled B72.3 GYK-DTPA immunoconjugate in beagle dogs. Nucl Med Biol 1993; 20:571-578.
30. Vriesendorp HM, Quadri SM, Stinson RL, Onyekwere OC, Shao Y, Klein JL, Leichner PK, Williams JR. Selection of reagents for human radioimmunotherapy. Int J Radiat Oncol Biol Phys 1991; 22:37-45.
31. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 1986; 27:1490-1497.
32. Wessels BW, Buchsbaum DJ. Dosimetry of radiolabeled antibodies. In: Smith AR, ed. Radiation Therapy Physics. New York: Springer-Verlag, 1995:365-384.
33. Volkert WA, Goeckeler WF, Ehrhardt GJ, Ketring AR. Therapeutic radionuclides: production and decay property considerations. J Nucl Med 1991; 32:174-185.
34. Mausner LF, Srivastava SC. Selection of radionuclides for radioimmunotherapy. Med Phys 1993; 20:503-509.
35. Muthuswamy M, Roberson PL, Ten Haken RK, Buchsbaum DJ. A quantitative study of radionuclide characteristics for radioimmunotherapy from 3D reconstructions using serial autoradiography. Int J Radiat Oncol Biol Phys 1996; 35:165-172.
36. DeNardo DA, DeNardo GL, Yuan A, Shen S, DeNardo SJ, Macey DJ, Lamborn KR, Mahe M, Groch MW, Erwin WD. Prediction of radiation doses from therapy using tracer studies with iodine-131 labeled antibodies. J Nucl Med 1996; 37:1970-1975.
37. Press OW, Eary JF, Appelbaum FR, Badger CC, Bernstein ID. Radiolabeled antibody therapy of lymphoma. In: Dana B, ed. Malignant Lymphomas, Including Hodgkin’s Disease: Diagnosis, Management and Special Problems. Boston: Kluwer Academic Publishers, 1993:127-145.
38. Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenberg H, Lee RE, Stein R, Siegel JA, Izon DO. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 1991; 9:548-564.
39. Miyamoto C, Brady LW, Rackover M, et al. Utilization of 125I monoclonal antibody in the management of primary glioblastoma multiforme. Radiat Oncol Invest 1995; 3:126-132.
40. Brady LW, Miyamoto C, Woo DV, Rackover M, Emrich J, Bender H, Dadparvar S, Steplewski Z, Koprowski H, Black P, Lazzaro B, Nair S, McCormack T, Nieves J, Morabito M, Eshleman J. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 1991; 22:225-230.
41. Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Reiman R, Felsberg GJ, Tien RD, Bigner SH, Zalutsky MR, Zhao XG, Wikstrand CJ, Pegram CN, Herndon JE II, Vick NA, Paleologos N, Fredericks RK, Schold SC Jr, Bigner DD. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res 1996; 2:963-972.
42. Richardson RB, Kemshead JT, Davies AG, Staddon GE, Jackson PC, Coakham HB, Lashford LS. Dosimetry of intrathecal iodine131 monoclonal antibody in cases of neoplastic meningitis. Eur J Nucl Med 1990; 17:42-48.
43. Juweid M, Sharkey RM, Swayne LC, Dunn R, Rubin A, Herskovic T, Hanley D, Goldenberg DM. Phase I dose-escalation trial of 131I-labeled MN-14 anti-carcinoembryonic antigen (CEA) monoclonal antibody in patients with epithelial ovarian cancer. Tumor Targeting 1996; 2:189.
44. Molthoff C, Prinssen W, van Hof A, Kenemans P, den Hollander W, Verheijen R. Chimeric monoclonal antibody MOv18 IgG in ovarian cancer patients: Influence of escalating doses of c-MOv18 protein. Tumor Targeting 1996; 2:190-191.
45. Larson SM, Carrasquillo JA, Colcher DC, Yokoyama K, Reynolds JC, Bacharach SA, Raubitchek A, Pace L, Finn RD, Rotman M, et al. Estimates of radiation absorbed dose for intraperitoneally administered iodine-131 radiolabeled B72.3 monoclonal antibody in patients with peritoneal carcinomatoses. J Nucl Med 1991; 32:1661-1667.
46. Stewart JSW, Hird V, Snook D, Sullivan M, Myers MJ, Epenetos AA. Intraperitoneal 131I-and 90Y-labeled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry. Int J Cancer 1988; 3(suppl):71-76.
47. Williams LE, Duda RB, Proffitt RT, Beatty BG, Beatty JD, Wong JYC, Shively JE, Paxton RJ. Tumor uptake as a function of tumor mass: a mathematic model. J Nucl Med 1988; 29:103-109.
48. O’Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995; 36:1902-1909.
49. Mayer R, Dillehay LE, Shao Y, Zhang Y-G, Song S, Bartholomew RM, Mackenson DG, Williams JR. Direct measurement of intratumor dose-rate distributions in experimental xenografts treated with 90Y-labeled radioimmunotherapy. Int J Radiat Oncol Biol Phys 1995; 32:147-157.
50. Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Bush SA, Hui TE, Martin PJ, Mitchell D, Press OW, et al. Development of marrow transplant regimen for acute leukemia using targeting hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995; 85:1122-1131.
51. Siegel JA, Goldenberg DM, Badger CC. Radioimmunotherapy dose estimation in patients with B-cell lymphoma. Med Phys 1993; 20:579-582.
52. Eary JF, Press OW, Badger CC, Durack LD, Richter KY, Addison SJ, Krohn KA, Fisher DR, Porter BA, Williams DL, Martin PJ, Appelbaum FR, Levy R, Brown SL, Miller RA, Nelp WB, Bernstein ID. Imaging and treatment of B-cell lymphoma. J Nucl Med 1990; 31:1257-1268.
53. Pollard KR, Bice AN, Eary JF, Durack LD, Lewellen TK. A method for imaging therapeutic doses of iodine-131 with a clinical gamma camera. J Nucl Med 1992; 33:771-776.
54. Dillman LT, Van der Lage FC. Radionuclide decay schemes and nuclear parameters for use in radiation-dose estimation. Soc Nuc Med MIRD pamphlet #10, 1975.
55. Snyder WS, Ford MR, Warner GG, Warner GG, Watson SB. “S” absorbed dose per unit cumulated activity for selected radionuclides and organs. Soc Nuc Med MIRD pamphlet #11, 1975.
56. Watson EE, StabinMG, Siegel JA.MIRD formulation.Med Phys 1993; 20:511-514.
57. Cristy M, Eckerman EF. Specific absorbed fractions of energy at various ages from internal photon source. ORNL/TM 1987; 1-7:8381.
58. Johnson TK. MABDOS: A generalized program for internal radionuclide dosimetry. Comput Meth Prog Biomed 1988; 27:159-176.
59. Johnson TK, Vessella RL. A generalized dosimetry schema for preferential uptake of monoclonal antibodies in radionuclide immunotherapy. J Nucl Med 1987; 28(suppl):680.
60. Strand SE, Jonsson BA, Ljungberg M, Tennvall J. Radioimmunotherapy dosimetry- a review. Acta Oncol 1993; 32:807-817.
61. Yang N-C, Leichner PK, Fishman EK, Siegelman SS, Frenkel TL, Wallace JR, Loudenslager DM. CT volumetrics of primary liver cancers. J Comput Assist Tomogr 1986; 10:621-628.
62. Erdi AK, Wessels BW, DeJager R, Erdi YE, Atkins FB, Yorke ED, Smith L, Huang E, Smiddy M, Murray J, et al. Tumor activity confirmation and isodose curve display for patients receiving iodine-131-labeled 16.88 human monoclonal antibody. Cancer 1994; 73:932-944.
63. Goris ML, Knox SA, Nielsen KR, Bouillant O. Organ modeling in the quantitation of planar images for distribution studies. Cancer 1994; 73:919-922.
64. Koral KF, Zasadny KR, Swailem FM, Buchbinder SF, Francis IR, Kaminski MS, Wahl RL. Importance of intra-therapy single-photon emission tomographic imaging in calculating tumour dosimetry for a lymphoma patient. Eur J Nucl Med 1991; 18:432-435.
65. Larson SM, Macapinlac HA, Scott AM, Divgi CR. Recent achievements in the development of radiolabeled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors. Acta Oncol 1993; 32:709-715.
66. DeNardo GL, Mahe MA, DeNardo SJ, Macey DJ, Mirick GR, Erwin WD, Groch MW. Body and blood clearance and marrow radiation dose of 131I-Lym-1 in patients with B-cell malignancies. Nucl Med Commun 1993; 14:587-595.
67. Siegel JA, Wessels BW, Watson EE, Stabin MG, Vriesendorp HM, Bradley EW, Badger CC, Brill AB, Kwok CS, Stickney DR, Eckerman KF, Fischer DR, Buchsbaum DJ, Order SE. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antib Immunoconjug Radiopharm 1990; 3:213-233.
68. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989; 62:679-694.
69. Wilder RB, DeNardo GL, Sheri S, Fowler JF, Wessels BW, DeNardo SJ. Application of the linear-quadratic model to myelotoxicity associated with radioimmunotherapy. Eur J Nucl Med 1996; 23:953-957.
70. Meredith RF, Johnson TK, Plott G, Macey DJ, Vessella RL, Wilson LA, Breitz HB, Williams LE. Dosimetry of solid tumors. Med Phys 1993; 20:583-592.
71. Behr TM, Sharkey RM, Juweid MI, Dunn RM, Ying Z, Zhang C-H, Siegel JA, Gold DV, Goldenberg DM. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors. Cancer Res 1996; 56:1805-1816.
72. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993; 34:689-694.
73. Zasadny KR, Gates VL, Fisher SJ, Kaminski MS, Wahl RL. Correlation of dosimetric parameters with hematological toxicity after radioimmunotherapy of non-Hodgkin’s lymphoma with I-131 anti-B1. Utility of a new parameter: “total body dose-lean.'' J Nucl Med 1995; 36:214P.
74. Breitz HB, Fisher DR, Wessels B. Correlation of bone marrow absorbed dose estimates with marrow toxicity. Tumor Targeting 1996; 2:173.
75. Meredith R, Khazaeli MB, Plott G, Wheeler R, Russell C, Shochat D, Norvitch M, Saletan S, LoBuglio A. Comparison of diagnostic and therapeutic doses of 131ILYM-1 in patients with non-Hodgkin’s lymphoma. Antibody Immunoconj Radiopharm 1993; 6:1-11.
76. Macey DJ, Murray JL, Grant EJ, Podoloff DA. Failure of the tracer principle for predicting red marrow doses in radioimmunotherapy patients challenged with interferon. Tumor Targeting 1996; 2:175-176.
77. DeNardo DA, Lim S, DeNardo GL, Shen S, O’Donnell RT, Yuan A, DeNardo SJ. Validity of marrow radiation dose estimation and semi-quantitative marrow indices for improved prediction of myelotoxicity. Tumor Targeting 1996; 2:178-179.
78. Goddu SM, Howell RW, Rao DV. Biologic dosimetry of bone marrow: implications for radionuclide therapy. Tumor Targeting 1996; 2:146.
79. Buchsbaum DJ, Khazaeli MB, Mayo MS, Roberson PL. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model. Clin Can Res 1999; 5(suppl):3153s-3159s.
80. Roberson PL, Dudek S, Buchsbaum DJ. Dosimetric comparison of bolus and continuous injections of CC49 monoclonal antibody in a colon cancer xenograft model. Cancer 1997; 80:2567-2575.
81. DeNardo SJ, Lamborn KR, Kroger LA, Miers LA, Kukis DL, Salako Q, Meares CF, DeNardo GL. The importance of time dose relationships in enhancement strategies for RIT of breast cancer. Tumor Targeting 1996; 2:148-149.
82. Roberson PL, Buchsbaum DJ. Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131iodine-labeled antibody for a colon cancer model. Cancer Res 1995; 55(suppl):5811s-5816s.
83. Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, Miller R, Brown S, Nelp WB, Krohn KA, Fisher D, DeSantes D, Porter B, Kidd P, Thomas ED, Bernstein ID. Treatment of refractory non-Hodgkin’s lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 1989; 7:1027-1038.
84. Valentine MA, Licciardi KA. Rescue from anti-IgM-induced programmed cell death by the B cell surface proteins CD20 and CD40. Eur J Immunol 1992; 22: 3141-3148.
85. Macklis RM, Beresford BA, Palayoor S, Sweeney S, Humm JL. Cell cycle alterations, apoptosis, and response to low-dose-rate radioimmunotherapy in lymphoma cells. Int J Radiat Oncol Biol Phys 1993; 27:643-650.
86. Macklis RM, Beresford BA, Humm JL. Radiobiologic studies of low-dose-rate 90Ylymphoma therapy. Cancer Res 1994; 73(suppl):966-973.
87. Murtha A, Rupnow B, Knox S. Low dose rate radiation favors apoptosis as a mechanism of cell death. Int J Radiat Oncol Biol Phys 1997; 39(suppl):242.
88. Illidge T, Cragg M, Glennie M. Cell cycle alterations, apoptosis and response to radioimmunotherapy in lymphoma cells. Proc ASCO 1997; 16:545a.
89. Tempero M, Colcher D, Dalrymple G, Harrison K, Augustine S, Schlom J, Linder J, Leichner P. High dose therapy with 131I conjugated monoclonal antibody CC49: a phase I trial. Antib Immunoconj Radiopharm 1993; 6:90.
90. Buckman R, De Angelis C, Shaw P, Covens A, Osborne R, Kerr I, Reed R, Michaels H, Woo M, Reilly R, Law J, Baumal R, Groves E, Marks A. Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecol Oncol 1992; 47:102-109.
91. Epenetos AA, Munro AJ, Stewart S, Rampling R, Lambert HE, McKenzie CG, Soutter P, Rahemtulla A, Hooker G, Sivolapenko GB, Snook D, Courtenay-Luck N, Dhokia B, Krausz T, Taylor-Papadimitrou J, Durbin H, Bodmer WF. Antibodyguided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 1987; 5:1890-1899.
92. Stewart JSW, Hird V, Snook D, Sullivan M, Hooker G, Courtenay-Luck N, Sivolapenko G, Griffiths M, Myers MJ, Lambert HE, Munro AJ, Epenetos AA. Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies. Int J Radiat Oncol Biol Phys 1989; 16:405-413.
93. Meredith RF, Khazaeli MB, Carabasi MH, LoBuglio AF. Radioimmunotherapy of prostate cancer. In: Riva P, ed. Therapy of Malignancies with Radioconjugate Monoclonal Antibodies: Present Possibilities and Future Perspectives. Langhorne, PA: Harwood Academic Publishers, 1999:321-331.
94. Murray JL. Radioimmunotherapy of colorectal cancer. In: Goldenberg DM, ed. Cancer Therapy with Radiolabeled Antibodies. Boca Raton, FL: CRC Press, 1995: 173-188.
95. Tempero M, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, Colcher D. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J Clin Oncol 1997; 15:1518-1528.
96. Juweid M, Sharkey RM, Alavi A, Swayne LC, Herskovic T, Hanley D, Rubin AD, Pereira M, Goldenberg DM. Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody. J Nucl Med 1997; 38:257-260.
97. Sun L-Q, Vogel C-A, Mirimanoff R-O, Coucke P, Donath A, Slosman DO, Mach J-P, Buchegger F. Increased therapeutic effect of concurrent radioimmunotherapy and radiotherapy of a human colon carcinoma in nude mice. Tumor Targeting 1996; 2:179.
98. Order SE, Vriesendorp HM, Klein JL, Leichner PK. A phase I study of 90Yttrium antiferritin: dose escalation and tumor dose. Antib Immunoconj Radiopharm 1988; 1:163-168.
99. Order SE, Klein JL, Leichner PK, Frincke J, Lollo C, Carlo DJ. 90Yttrium antiferritin- a new therapeutic radiolabeled antibody. Int J Radiat Oncol Biol Phys 1986; 12:277-281.
100. Tschmelitsch J, Welt S, Barendswaard E, Yao T, Cohen A, Old L. Enhanced antitumor activity of combination radiotherapy (131I-monoclonal antibody A33) with chemotherapy (fluorouracil). Proc Am Assoc Cancer Res 1996; 37:469.
101. Dunn RM, Juweid M, Behr TM, Siegel JA, Sharkey RM, Goldenberg DM. Therapeutic potential in patients with minimal residual disease using 131I-labeled antibodies for radioimmunotherapy (RAIT). Tumor Targeting 1996; 2:145-146.
102. Buchsbaum DJ. Experimental tumor targeting with radiolabeled ligands. Cancer 1997; 80:2371-2377.
103. Scheinberg DA. Current applications of monoclonal antibodies for the therapy of hematopoietic cancers. Curr Opin Immunol 1991; 3:679-684.
104. Chatal J-F, Peltier P, Bardies M, Chetanneau A, Thedrez P, Faivre-Chauvet A, Gestin JF. Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy? Eur J Nucl Med 1992; 19:205-213.
105. Goldenberg DM. Monoclonal antibodies in cancer detection and therapy. Am J Med 1993; 94:297-312.
106. Goldenberg DM, Blumenthal RD, Sharkey RM. Biological and clinical perspectives of cancer imaging and therapy with radiolabeled antibodies. Semin Cancer Biol 1990; 1:217-225.
107. Sharkey RM, Blumenthal RD, Goldenberg DM. Development of cancer radioimmunotherapy and its potential use as an adjuvant treatment. In: Goldenberg DM, ed. Cancer Therapy with Radiolabeled Antibodies. Boca Raton, FL: CRC Press, 1995:101-114.
108. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles T-M, Grillo-Lopez A, Chinn P, Varns C, Ning S-C, Fowler S, Deb N, Becker M, Marquez C, Levy R. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996; 2:457-470.
109. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14:1974-1981.
110. Zasadny KR, Gates VL, Francis I, Fisher S, Kaminski MS, Wahl RL. Normal organ and tumor dosimetry of I-131-anti-B1 (anti-CD20) radioimmunotherapy at nonmarrow ablative doses. J Nucl Med 1997; 38(suppl):230.
111. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T, Bernstein ID. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346:336-340.
112. Lamborn KR, DeNardo GL, DeNardo SJ, Goldstein DS, Shen S, Larkin EC, Kroger LA. Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies. Clin Cancer Res 1997; 3:1253-1260.
113. Kalofonos HP, Pawlikowska TR, Hemingway A, Courtenay-Luck N, Dhokia B, Snook D, Sivolapenko GB, Hooker GR, McKenzie CG, Lavender PJ, Thomas DGT, Epenetos AA. Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med 1989; 30:1636-1645.
114. Riva P, Arista A, Tison V, Sturiale C, Franceschi G, Spinelli A, Riva N, Casi M, Moscatelli G, Frattarelli M. Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors. Cancer 1994; 73:1076-1082.
115. Riva P, Marangolo M, Tison V, Armaroli L, Moscatelli G, Franceschi G, Spinelli A, Vecchietti G, Morigi P, Tassini R, et al. Treatment of metastatic colorectal cancer by means of specific monoclonal antibodies conjugated with iodine-131: A phase II study. Nucl Med Biol 1991; 18:109-119.
116. Westlin J-E, Snook D, Nilsson S, Husin S, Enblad P, Stavrou S, Epenetos AA, Bergh J. Intravenous and intratumoural therapy of patients with malignant gliomas with 90yttrium-labelled monoclonal antibody MUC 2-63. In: Epenetos A, ed. Monoclonal Antibodies 2: Applications in Clinical Oncology. London: Chapman & Hall Medical, 1993:17-25.
117. Riva P, Arista A, Sturiale C, Moscatelli G, Tison V, Mariani M, Seccamani E, Lazzari S, Fagioli L, Franceschi G, Sarti G, Riva N, Natali PG, Zardi L, Scassellati GA. Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labeled anti-tenascin monoclonal antibody BC-2. Int J Cancer 1992; 51:7-13.
118. Franceschi G, Arista A, Casi M, Cremonini AM, Riva N, Vergoni M, Riva P. Intralesional radioimmunotherapy of high grade glioma: clinical experiences in 59 patients. Tumor Targeting 1996; 2:164.
119. Hird V, Stewart JS, Snook D, Dhokia B, Coulter C, Lambert HE, Mason WP, Soutter WP, Epenetos AA. Intraperitoneally administered 90Y-labelled monoclonal antibodies as a third line of treatment in ovarian cancer. A phase 1-2 trial: problems encountered and possible solutions. Br J Cancer 1990; 10(suppl):48-51.
120. Hnatowich DJ, Mardirossian G, Rose PG, Kinders B, Rusckowski M, Stevens S, Hunter R, Griffin T, Brill AB. Intraperitoneal therapy of ovarian cancer with yttrium-90-labeled monoclonal antibodies, preliminary observations. Antib Immunoconj Radiopharm 1991; 4(3):359-371.
121. Jacobs AJ, Fer M, Su FM, Breitz H, Thompson J, Goodgold H, Cain J, Heaps J, Weiden P. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response. Obstet Gynecol 1993; 82:586-593.
122. Breitz HB, Durham JS, Fisher DR, Weiden PL. Radiation-absorbed dose estimates to normal organs following intraperitoneal 186Re-labeled monoclonal antibody: methods and results. Cancer Res 1995; 55(suppl):5817s-5822s.
123. Breitz HB, Durham JS, Fisher DR, Weiden PL, DeNardo GL, Goodgold HM, Nelp WB. Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody. J Nucl Med 1995; 36:754-761.
124. Meredith RF, Partridge EE, Alvarez RD, Khazaeli MB, Plott G, Russell CD, Wheeler RH, Liu T, Grizzle WE, Schlom J, LoBuglio AF. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med 1996; 37: 1491-1496.
125. Meredith RF, Macey DJ, Plott WE, Brezovich IA, Khazaeli MB, Alvarez R, Partridge E, Russell CD, Wheeler RH, Liu T, Elliott G, Schlom J, LoBuglio AF. Radiation dose estimates from intraperitoneal radioimmunotherapy with 177Lu-CC49. Proc 6th Int Radiopharm Dosimetry Symp 1999; 1:158-171.
126. Alvarez RD, Partridge EE, Khazaeli MB, Plott G, Austin M, Kilgore L, Russell CD, Liu T, Grizzle WE, Schlom J, LoBuglio AF, Meredith RF. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol 1997; 65:94-101.
127. Kramer EL, DeNardo SJ, Liebes L, Kroger LA, Noz ME, Mizrachi H, Salako QA, Furmanski P, Glenn SD, DeNardo GL, et al. Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I study. J Nucl Med 1993; 34:1067-1074.
128. Schrier DM, Stemmer SM, Johnson T, Kasliwal R, Lear J, Matthes S, Taffs S, Dufton C, Glenn SD, Butchko G, Ceriani RL, Rovira D, Bunn P, Shpall EJ, Bearman SI, Purdy M, Cagnini P, Jones RB. High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial. Cancer Res 1995; 55(suppl):5921s-5924s.
129. Wong JYC, Williams LE, Yamauchi DM, Odom-Maryon T, Esteban JM, Neumaier M, WuAM, Johnson DK, Primus FJ, Shively JE, Raubitschek AA. Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial. Cancer Res 1995; 55(suppl):5929s-5934s.
130. Richman CM, DeNardo SJ, O’Grady LF, DeNardo GL. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res 1995; 55(suppl):5916s-5920s.
131. Leichner PK, Klein JL, Garrison JB, Jenkins RE, Nickoloff EL, Ettinger DS, Order SE. Dosimetry of 131I-labeled anti-ferritin in hepatoma: a model for radioimmunoglobulin dosimetry. Int J Radiat Oncol Biol Phys 1981; 7:323-333.
132. Order SE, Stillwagon GB, Klein JL, Leichner PK, Siegelman SS, Fishman EK, Ettinger DS, Haulk T, Kopher K, Finney K, et al. Iodine-131-antiferritin, a new treatment modality in hepatoma: a radiation therapy oncology group study. J Clin Oncol 1985; 3:1573-1582.
133. de Bree R, Roos JC, Quak JJ, den Hollander W, Snow GB, van Dongen GAMS. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res 1995; 1:591-598.
134. Breitz HB, Weiden PL, Vanderheyden J-L, Appelbaum JW, Bjorn MJ, Fer MF, Wolf SB, Ratliff BA, Seiler CA, Foisie DC, Fisher DR, Schroff RW, Fritzberg AR, Abrams PG. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials. J Nucl Med 1992; 33: 1099-1112.
135. Begent RHJ, Ledermann JA, Green AJ, Bagshawe KD, Riggs SJ, Searle F, Keep PA, Adam T, Dale RG, Glaser MG. Antibody distribution and dosimetry in patients receiving radiolabeled antibody therapy for colorectal cancer. Br J Cancer 1989; 60:406-412.
136. Meredith RF, Khazaeli MB, Plott WE, Brezovich IA, Russell CD, Wheeler RH, Spencer SA, LoBuglio AF. Comparison of two mouse/human chimeric antibodies in patients with metastatic colon cancer. Antib Immunoconj Radiopharm 1992; 5: 75-80.
137. Meredith RF, LoBuglio AF, Plott WE, Orr RA, Brezovich IA, Russell CD, Harvey EB, Yester MV, Wagner AJ, Spencer SA, Wheeler RH, Saleh MN, Rogers KJ, Polansky A, Salter MM, Khazaeli MB. Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgGI, 17-1A monoclonal antibody. J Nucl Med 1991; 32:1162-1168.
138. Steffens MG, Boerman OC, Oosterhof GON, Koenders E, Oosterwijk-Wakka JC, Witjes JA, Cebruyne FMJ, Corstens FHM, Oosterwijk E. Targeting and therapeutic potential of 131I-labeled chimeric monoclonal antibody G250 in renal cell carcinoma patients. Tumor Targeting 1996; 2:164.
139. Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Swayne LC, Ying Z, Siegel JA, Goldenberg DM. Radioimmunotherapy of CEA-expressing cancers: results of a phase I/II trial with 131I-labeled murine anti-CEA NP-4 IgG1. Tumor Targeting 1996; 2:162.
140. Deb N, Goris M, Trisler K, Fowler S, Saal J, Ning S, Becker M, Marquez C, Knox S. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res 1996; 2:1289-1297.
141. Abdel-Nabi HH, Spaulding M, Farrell E, Derby L, Lamonica D. Treatment of refractory prostate carcinoma with Y-90 KC4. J Nucl Med 1995; 36(suppl):213P.
142. Lashford L, Jones D, Pritchard J, Gordon I, Breatnach F, Kemshead JT. Therapeutic application of radiolabeled monoclonal antibody UJ13A in children with disseminated neuroblastoma. NCI Monogr 1987; 3:53-57.
143. Vessella RL. Radioimmunoconjugates in renal cell carcinoma. In: Debruyne FMJ, Bukowski RM, Pontes JE, et al., eds. Immunotherapy of Renal Cell Carcinoma. Heidelberg: Springer-Verlag, 1991:38-46.
144. Murray JL, Macey DJ, Kasi LP, Rieger P, Cunningham J, Bhadkamkar V, Zhang HZ, Schlom J, Rosenblum MG, Podoloff DA. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer. Cancer 1994; 73(suppl):1057-1066.
145. Mardirossian G, Brill AB, Dwyer KM, Kahn D, Nelp W. Radiation absorbed dose from indium-111-CYT-356. J Nucl Med 1996; 37:1583-1588.
146. Juweid ME, Sharkey RM, Behr T, Swayne LC, Dunn R, Siegel J, Goldenberg DM. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab’)2. J Nucl Med 1996; 37:1504-1510.